The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
Abstract
BACKGROUND: The p38 mitogen-activated protein kinase (MAPK) is activated by various pro-inflammatory and stressful stimuli. Mounting evidence suggests that the p38 MAPK signaling cascade is involved in various biological responses other than inflammation such as cell proliferation, differentiation, apoptosis and invasion, suggesting that the p38 MAPK can serve as a potential therapeutic target for the treatment of not only inflammatory diseases but also cancer. METHODS: The unique characteristics of p38 MAPK are summarized with regard to activation and function of p38 MAPK signaling cascades. We then discuss the involvement of p38 MAPK in diseases and the implications of the possible therapeutic use of p38 MAPK inhibitors. The p38 MAPK inhibitors that have been used in the in vitro/in vivo systems as well as in the clinical trials are summarized. RESULTS/CONCLUSION: The p38 MAPK plays an important role in key cellular processes related to inflammation and cancer. Understanding the signal transduction mechanisms and gene regulation by p38 MAPK provides useful information in the development of p38 MAPK inhibitors with therapeutic benefits with reduced side effects. In this review, we summarize and present the list of p38 MAPK inhibitors in in vitro/in vivo studies as well as in clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both signaling pathways are key regulators of inflammation and pro-inflammatory responses, which are considered targets for developing anti-inflammatory therapeutic agents [23–26].”
From The potential of GHK as an anti-aging peptide (2020) · cites this paper as [25]
Citations
Cites
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,034
Kyriakis, J. M., & Avruch, J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.807 · Cited by 3,382
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991) · Cell · doi:10.1016/0092-8674(91)90642-c · Cited by 2,720
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Raingeaud, J., Gupta, S., Rogers, J. S., Dickens, M., Han, J., Ulevitch, R. J., & Davis, R. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7420 · Cited by 2,241
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
The p38 signal transduction pathway Activation and function
Ono, K., & Han, J. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(99)00071-6 · Cited by 1,571
Kaminska, B. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.017 · Cited by 1,285
Research works printed but not linked: 15
- Kim MS, 2003, Cancer Res, 63, 5454
- 10.1111/j.1572-0241.2003.07660.x · doi:10.1111/j.1572-0241.2003.07660.x · Paper page
- Lim SJ, 2006, Oncol Rep, 16, 1131
- Han YC, 2007, Ai Zheng, 26, 48
- Simon C, 1998, Cancer Res, 58, 1135
- She QB, 2001, Cancer Res, 61, 1604
- Karahashi H, 2000, Biochem Biophys Acta, 1502, 207
- Kim ES, 2004, Int J Oncol, 25, 1375
- Dominguez C, 2005, Curr Opin Drug Discov Devel, 8, 421
- Mongin-Bulewski C, 2002, Drug Discovery Technology 2002 (Part V) - Overnight Report
- Alten RE, 2009, Ann Rheum Dis
- Behr TM, 2003, Curr Opin Investig Drugs, 4, 1059
- Braddock M, 2003, Inflammation in drug discovery and development SRI's seventh international meeting
- Pargellis C, 2003, Curr Opin Investig Drugs, 4, 566
- Fitzgerald CE, 2003, MAP kinase quinazoline and pyridol-pyrimidine inhibitor specificity Nat Struct Biol, 10, 764
Cited by
Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV
Stukalov, A., Girault, V., Grass, V., Karayel, O., Bergant, V., Urban, C., Haas, D. A., Huang, Y., Oubraham, L., Wang, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03493-4 · Cited by 685
Reactive Oxygen Species in the Activation of MAP Kinases
Son, Y., Kim, S., Chung, H.-T., & Pae, H.-O. (2013) · Methods in Enzymology · doi:10.1016/b978-0-12-405881-1.00002-1 · Cited by 464
Cornel, A. M., Mimpen, I. L., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12071760 · Cited by 464
Ma, L., Wu, F., Shao, Q., Chen, G., Xu, L., & Lu, F. (2021) · Drug Design, Development and Therapy · doi:10.2147/dddt.s319260 · Cited by 273
de Lima, R. M. T., dos Reis, A. C., de Menezes, A. P. M., Santos, J. V. D. O., Filho, J. W. G. D. O., Ferreira, J. R. D. O., de Alencar, M. V. O. B., da Mata, A. M. O. F., Khan, I. N., Islam, A., et al. (2018) · Phytotherapy Research · doi:10.1002/ptr.6134 · Cited by 256
Metadata
- Authors
- Yong, H.-Y., Koh, M.-S., & Moon, A.
- Affiliations
- Duksung Women's University (KR)
- ORCID
- Moon, Aree
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-10-23
- Volume
- 18
- Issue
- 12
- Pages
- 1893-1905
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2049204919
- Semantic Scholar
- bc7dcb42a3c3bc9e5014f4072d16d27a6600bb7a
- Cited by
- 422
- References
- 141
- Citations by year
- 2026: 20 · 2025: 50 · 2024: 77 · 2023: 46 · 2022: 52 · 2021: 27 · 2020: 22 · 2019: 13 · 2018: 10 · 2017: 10 · 2016: 11 · 2015: 17 · 2014: 14 · 2013: 21 · 2012: 15
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Korea Science and Engineering Foundation
- Johnson and Johnson
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- p38 MAPK, MAPK inhibitors, inflammatory diseases, cancer, MAPK signaling, signal transduction, gene expression regulation, apoptosis, cell proliferation, clinical trials, drug development
- MeSH terms
- Clinical Trials as Topic, Drug Evaluation, Preclinical, Enzyme Inhibitors, Humans, Inflammation, Neoplasms, Signal Transduction, Drugs, Investigational, MAP Kinase Signaling System, p38 Mitogen-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. https://app.cochat.ai/papers/10.1517/13543780903321490
- The paper
- Yong, H.-Y., Koh, M.-S., & Moon, A. (2009). The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780903321490
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.